INDUSTRY × Interventional × Neoplasms by Site × Clear all
NCT03157128 2026-04-16

LIBRETTO-001

Eli Lilly and Company

Phase 1/2 Active not recruiting
857 enrolled 24 charts 6 FDA
NCT07216443 2026-04-15

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Orca Biosystems, Inc.

Phase 2 Recruiting
80 enrolled
NCT05462717 2026-04-08

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

Revolution Medicines, Inc.

Phase 1 Active not recruiting
222 enrolled
NCT07222800 2026-04-08

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

Pfizer

Phase 3 Recruiting
800 enrolled
NCT03093116 2026-04-03

TRIDENT-1

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
500 enrolled 5 FDA
NCT06128551 2026-02-10

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Revolution Medicines, Inc.

Phase 1/2 Recruiting
534 enrolled
NCT03899792 2026-01-06

LIBRETTO-121

Eli Lilly and Company

Phase 1/2 Active not recruiting
36 enrolled 13 charts 4 FDA
NCT04198766 2025-12-18

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Inhibrx Biosciences, Inc

Phase 1/2 Active not recruiting
296 enrolled
NCT07162883 2025-09-09

Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)

Qilu Pharmaceutical Co., Ltd.

Phase 3 Not yet recruiting
122 enrolled
NCT05592626 2025-07-09

START-001

Marengo Therapeutics, Inc.

Phase 1/2 Recruiting
365 enrolled
NCT03037385 2025-05-31

ARROW

Hoffmann-La Roche

Phase 1/2 Completed
590 enrolled 58 charts 8 FDA
NCT04996875 2025-05-30

APEX

Cogent Biosciences, Inc.

Phase 2 Recruiting
140 enrolled
NCT04104776 2025-05-15

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Novartis

Phase 1/2 Recruiting
275 enrolled
NCT04774952 2025-04-15

Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors

Revolution Medicines, Inc.

Phase 1 Completed
58 enrolled
NCT04249947 2025-02-17

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Poseida Therapeutics, Inc.

Phase 1 Terminated
40 enrolled